SCHEMBL13293442

SCHEMBL13293442

Cc1ccc2c(c1)c1c(n2CCc2cnc(C(F)(F)F)cn2)CCN(C)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 18/20 0.62
HTR6 P50406 17/20 0.62
ADRA2A P08913 3/20 0.53
HTR2A P28223 3/20 0.53
HTR2C P28335 3/20 0.53
HTR7 P34969 3/20 0.53
ADRA1A P35348 3/20 0.53
DRD2 P14416 2/20 0.53
BCHE P06276 1/20 0.53
ADRA2B P18089 1/20 0.53
ADRA2C P18825 1/20 0.53
ACHE P22303 1/20 0.53
HRH2 P25021 1/20 0.53
ADRA1D P25100 1/20 0.53
HTR1D P28221 1/20 0.53
HTR1E P28566 1/20 0.53
ADRA1B P35368 1/20 0.53
DRD3 P35462 1/20 0.53
HTR2B P41595 1/20 0.53
HTR5A P47898 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4128249 0.93 HTR6 (0.72) HRH1HTR6ADRA2AHTR2AHTR2C
SCHEMBL13293414 0.89 HTR6 (0.49) HRH1HTR6ADRA2AHTR2AHTR2C
SCHEMBL18193456 0.89 HRH1 (0.65) HRH1HTR6ADRA2AHTR2AHTR2C
SCHEMBL3229858 0.86 HRH1 (0.66) HRH1HTR6ADRA2AHTR2AHTR2C
SCHEMBL18193105 0.85 HRH1 (0.56) HRH1HTR6ADRA2AHTR2AHTR2C
SCHEMBL18193446 0.85 HRH1 (0.54) HRH1HTR6ADRA2AHTR2AHTR2C
SCHEMBL4139155 0.83 HTR6 (0.58) HRH1HTR6ADRA2AHTR2AHTR2C
SCHEMBL13293436 0.82 HRH1 (0.63) HRH1HTR6ADRA2AHTR2AHTR2C
SCHEMBL3723410 0.81 HRH1 (0.77) HRH1HTR6ADRA2AHTR2AHTR2C
SCHEMBL13293444 0.80 HRH1 (0.58) HRH1HTR6ADRA2AHTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9481676-B2 Azepino[4,5-B]indoles and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2016-11-01 US disclosed
US-9481676-B2 Azepino[4,5-B]indoles and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2016-11-01 US disclosed
US-9409910-B2 Azepino[4,5-B]indoles and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2016-08-09 US disclosed
US-9409910-B2 Azepino[4,5-B]indoles and methods of use MEDIVATION TECHNOLOGIES, INC. (US) 2016-08-09 US disclosed
US-20140088087-A1 AZEPINO[4,5-B]INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2014-03-27 US disclosed
US-20140088087-A1 AZEPINO[4,5-B]INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2014-03-27 US disclosed
US-20130190295-A1 AZEPINO[4,5-B]INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2013-07-25 US disclosed
US-20100152163-A1 AZEPINO[4,5-B]INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. 2010-06-17 US disclosed
US-20100152163-A1 AZEPINO[4,5-B]INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. 2010-06-17 US disclosed
WO-2010051503-A1 AZEPINO [4, 5-B] INDOLES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190295-A1 AZEPINO[4,5-B]INDOLES AND METHODS OF USE HTR2C, HTR5A, HTR4 HRH1 32/4885HTR6 14/4885ADRA2A 45/4885
US-20100152163-A1 AZEPINO[4,5-B]INDOLES AND METHODS OF USE HTR2C, HTR5A, HTR4 HRH1 32/4885HTR6 14/4885ADRA2A 45/4885
US-20140088087-A1 AZEPINO[4,5-B]INDOLES AND METHODS OF USE HTR2C, HTR5A, HTR4 HRH1 32/4885HTR6 14/4885ADRA2A 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.